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Abstract
OXA1, the mitochondrial member of the YidC/Alb3/Oxa1 membrane
protein insertase family, is required for the assembly of oxidative
phosphorylation complexes IV and V in yeast. However, depletion
of human OXA1 (OXA1L) was previously reported to impair assem-
bly of complexes I and V only. We report a patient presenting with
severe encephalopathy, hypotonia and developmental delay who
died at 5 years showing complex IV deficiency in skeletal muscle.
Whole exome sequencing identified biallelic OXA1L variants
(c.500_507dup, p.(Ser170Glnfs*18) and c.620G>T, p.(Cys207Phe))
that segregated with disease. Patient muscle and fibroblasts
showed decreased OXA1L and subunits of complexes IV and V.
Crucially, expression of wild-type human OXA1L in patient fibrob-
lasts rescued the complex IV and V defects. Targeted depletion of
OXA1L in human cells or Drosophila melanogaster caused defects in
the assembly of complexes I, IV and V, consistent with patient
data. Immunoprecipitation of OXA1L revealed the enrichment of
mtDNA-encoded subunits of complexes I, IV and V. Our data verify
the pathogenicity of these OXA1L variants and demonstrate that
OXA1L is required for the assembly of multiple respiratory chain
complexes.
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Introduction
Mitochondrial disorders encompass a wide range of clinical pheno-
types and are genetically heterogeneous. Mitochondrial dysfunction
can arise from mutations in either the maternally inherited mito-
chondrial genome (mtDNA) or in nuclear genes that encode mito-
chondrial proteins. The 13 mtDNA-encoded polypeptides are
essential components of the oxidative phosphorylation (OXPHOS)
system. Many nuclear genetic defects causing mitochondrial disease
are in gene products required for maintaining correct expression of
mtDNA. These include proteins involved in replication, mtDNA
maintenance, transcription, mtRNA processing, maturation and
translation (Lightowlers et al, 2015).
In recent years, next-generation sequencing (NGS) technologies,
particularly whole exome sequencing (WES), have proven success-
ful in identifying an increasing number of mutations in genes caus-
ing primary mitochondrial disorders (Calvo et al, 2012; Taylor et al,
2014; Wortmann et al, 2015; Kohda et al, 2016; Pronicka et al,
2016). There are currently more than 250 nuclear-encoded genes
associated with mitochondrial disease (Mayr et al, 2015; Alston
et al, 2017; Frazier et al, 2017). However, considering the mito-
chondrial proteome is estimated to include approximately 1,200
proteins, it is likely that there are many more candidate genes still
to be described. One such gene is OXA1L, which has long been
proposed as a candidate gene to be screened for mutations in
patients presenting with combined respiratory chain deficiencies
(Rotig et al, 1997). To date, no mutations have been linked to mito-
chondrial disease (Coenen et al, 2005).
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OXA1L is a member of the YidC/Alb3/Oxa1 membrane protein
insertase family (Hennon et al, 2015). The yeast orthologue of
OXA1L, Oxa1p, was identified as an important factor for the assem-
bly of complex IV (Bonnefoy et al, 1994a) and has also been shown
to be important for the assembly of complex V (Altamura et al,
1996). Oxa1p interacts with the mitoribosome (Jia et al, 2003;
Kohler et al, 2009) and is required for the co-translational
membrane insertion of mitochondrial-encoded Atp6p, Atp9p,
Cox1p, Cox2p, Cox3p and Cytb (Hell et al, 1997, 1998, 2001; Jia
et al, 2007). Oxa1p also appears to have a direct role in the insertion
of nuclear-encoded inner mitochondrial membrane (IMM) proteins
(Hell et al, 2001) including Oxa1p itself (Hell et al, 1998) and an
indirect effect on many more IMM proteins including several
metabolite transporters (Hildenbeutel et al, 2012), since Oxa1p is
crucial for the biogenesis of the Tim18-Sdh3 module of the carrier
translocase (Stiller et al, 2016).
The majority of studies into the function of Oxa1 have been
conducted in yeast. Human OXA1L shares 33% identity with the
Oxa1p yeast protein and was identified as a homologue by func-
tional complementation and expression of the human gene into an
Oxa1p null strain of Saccharomyces cerevisiae. This partially rescued
the phenotype of impaired cytochrome c oxidase (COX) assembly,
suggesting that OXA1L likely performs a similar role in human cells
(Bonnefoy et al, 1994b). Indeed, human OXA1L has since been
reported to bind to the mammalian mitoribosome via its C-terminal
tail (Haque et al, 2010). In contrast to yeast, shRNA-mediated
knockdown of OXA1L in human cells was shown to cause a defect
in complex I and complex V assembly, but did not affect complex IV
(Stiburek et al, 2007). As other insertases may be present in mito-
chondria, clarification into the importance of OXA1L is required.
Here, we present the clinical, biochemical and molecular char-
acterisation of a patient with a severe, childhood-onset mitochon-
drial encephalopathy and combined respiratory chain deficiency
due to biallelic variants in OXA1L identified by WES. Results from
cellular and biochemical approaches suggest that OXA1L plays a
major role as the insertase for the biogenesis of respiratory chain
complexes.
Results
Case report
The index case, a 5-year-old male, was born to non-consanguineous
healthy Chinese parents. Three previous pregnancies had resulted in
miscarriages in the first and second trimesters without obvious
cause, but this pregnancy had been uneventful, though delivery was
complicated by a clavicular fracture. He had a good birthweight of
4.1kg and did not require resuscitation with Apgars recorded as 91
and 105. He showed signs of severe hypotonia from birth with
subsequent neurodevelopmental delay, achieving independent
sitting at 12 months, but never being able to stand or walk.
Language skills were also severely delayed in that he was unable to
understand even simple instructions and made no attempt to speak
or supplement communication with non-verbal behaviour. He was
reliant on parents for all activities of daily living. Obstructive sleep
apnoea was confirmed by polysomnography at the age of 3 years,
and he had a tonsillectomy prior to commencing non-invasive
nocturnal ventilation. On examination at 4 years, he was noted to
be obese (32 kg) and exhibited generalised weakness, hypotonia
and areflexia in his lower limbs. Iron deficiency anaemia was identi-
fied though the cause was unclear. Brain MRI revealed dysgenesis
of the corpus callosum but was otherwise normal (Fig EV1). Electro-
physiological testing showed normal motor nerve velocities, but low
amplitude CMAPs and a neurogenic pattern on electromyography.
At 5 years, he presented with a brief febrile illness associated with a
mild metabolic acidosis (venous lactate 2.48 mmol/l, normal range
0.7–2.1 mmol/l) and leucocytosis. Further metabolic workup
revealed increased serum alanine (520 lmol/l; normal
range < 416), but ammonia, CDG and biotinidase activity were
normal, as was PDHc activity in patient fibroblasts. Acylcarnitines
and urinary organic acids were not determined. His condition deteri-
orated rapidly with generalised seizures and encephalopathy prior
to a cardiorespiratory arrest from which he could not be resusci-
tated. An older female sibling, also considered to have neurodevel-
opmental delay, died in China aged 12 months. This death was also
preceded by a febrile illness, but the cause remains unclear. A
younger male sibling was born following pre-natal testing for the
genetic mutation identified in the index case (Fig 1A).
Diagnostic mitochondrial investigations of patient muscle
Postmortem tissue from the patient was made available for diagnos-
tic evaluation of suspected mitochondrial disease. Histopathological
assessment, including routine histology and oxidative enzyme histo-
chemistry, showed no obvious morphological abnormalities
although the individual COX staining was weak, which was con-
firmed by a generalised decrease in COX activity following sequen-
tial COX-SDH histochemistry (Fig 1B). In agreement with these
observations, the assessment of mitochondrial respiratory chain
complex activities in skeletal muscle showed decreased activity of
complex IV, with activities of complexes I-III within the normal
range (Fig 1C).
Molecular genetic investigations
A prominent complex IV deficiency in patient skeletal muscle demon-
strated a mitochondrial aetiology. Assessment of mtDNA in patient
samples showed no mutations, and mtDNA copy number was
normal. Candidate genes including SURF1, SCO1, SCO2, COX10,
COX14, COX15, COX20, COA3, COA5 and APOPT1were screened but
no pathogenic variants were identified. Further analysis using WES
revealed biallelic variants in OXA1L (NM_005015.3) c.500_507dup,
p.(Ser170Glnfs*18) (ClinVar: SCV000803663) and c.620G>T,
p.(Cys207Phe) (ClinVar: SCV000803664). The c.500_507dup variant
is not listed in the gnomAD database (http://gnomad.broadinstitute.
org), whereas the c.620G>T variant is present in one individual of
East Asian ethnicity (1 in 246,200, allele frequency 0.00041%).
Sanger sequencing confirmed the presence of the variants and that
the variants segregated with disease in the family (Fig 1D and E). The
c.620G>T OXA1L variant is predicted to result in a p.(Cys207Phe)
amino acid substitution, but is also predicted to affect splicing due to
this variant being at the first nucleotide of the exon. Analysis of cDNA
confirmed a splicing defect with evidence of skipping of exon 4
(Fig 1F) demonstrating the c.620G>T variant causes an amino acid
substitution and exon skipping (p.[Cys207Phe, Cys207_Glu254del]),
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with the amino acid substitution affecting the moderately well-
conserved Cys207 residue (Fig 1G). Since one variant causes a frame-
shift and the other affects splicing, American College of Medical
Genetics and Genomics (ACMGG) guidelines consider these to be
loss-of-function alleles. MutationTaster (www.mutationtaster.org)
predicts the c.620G>T variant to be disease-causing, and the variant
has a scaled CADD score of 24.9 (http://cadd.gs.washington.edu).
Neuropathology
The pons exhibited bilateral cavitation with microvascular prolifera-
tion, which severely affected the pedunculopontine (PPN) nucleus
(Fig EV2Ai, ii and iii) and was accompanied by astrogliosis
(Fig EV2Aiv) and microglial activation (Fig EV2Av) with preserved
neuronal cell density. PPN neurons and the surrounding neuropil
showed profound loss in the levels of complex I subunits NDUFB8
and NDUFS3 expression (Fig EV2Avi), while nuclear-encoded
complex II subunit SDHA (Fig EV2Aviii), mitochondrially encoded
complex IV subunit COXI (Fig EV2Ax) and complex V subunit ATP5B
(Fig EV2Axii) levels were maintained. Substantia nigra neurons
showed a similar pattern of NDUFS3-specific loss (Fig EV2Bi), while
SDHA (Fig EV2Bii), COXI (Fig EV2Biii) and ATP5B (Fig EV2Biv)
were preserved. The spinal cord demonstrates prominent demyelina-
tion of the fasciculus gracile tract (Fig EV2Ci and ii) with relative
preservation of myelin in the fasciculus cuneatus (Fig EV2Ciii). The
motor neurons were well populated with remaining neurons exhibit-
ing reduced levels of NDUFB8 (Fig EV2Civ) and NDUFS3
(Fig EV2Cv), while SDHA (Fig EV2Cvi), COXI (Fig EV2Cvii) and
ATP5B (Fig EV2Cviii) were apparently normal within neurons.
Macroscopically, the frontal lobe was atrophic, and the corpus callo-
sum was affected by hypoplasia, particularly in the splenium
(Fig EV3A). The basal ganglia were also affected by microcavitation
affecting the thalamus (Fig EV3B), and striatum with microvascular
proliferation, activated microglia and reactive gliosis (Fig EV3B). The
cortex revealed a normal laminar architecture, with discrete cell loss
affecting the frontal cortex. Slight downregulation in the levels of
NDUFS3 and NDUFB8 relative to SDHA, COXI and ATP5B was
observed in neurons within the frontal (Fig EV3C), parietal
(Fig EV3D) and occipital cortex (Fig EV3E). The architecture of the
cerebellum was preserved with normal Purkinje cell density, minimal
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Figure 1. Molecular genetics and biochemical studies of OXA1L variants.
A Family pedigree detailing recessive inheritance pattern of OXA1L variants, index case denoted with red asterisk.
B Haematoxylin & Eosin (i) and modified Gomori trichrome (ii) staining demonstrate expected variability in muscle fibre size, with isolated internal nuclei. There is
no evidence of regenerative fibres or necrosis, nor subsarcolemmal mitochondrial aggregates typical of “ragged-red” changes. The absence of mitochondrial
proliferation is confirmed in both the NADH-tetrazolium reductase (iii) and SDH (iv) reactions. The individual COX reaction (v) reveals a uniform loss of enzyme
reactivity across the muscle cryosection, accentuated in the sequential COX-SDH reaction (vi) in which COX-deficient, SDH-positive fibres are prominent uniformly.
Scale bar shown is 50 lm.
C Activity of mitochondrial respiratory complexes in control (red) and patient (blue) skeletal muscle samples. Mean enzyme activities of control muscle (n = 25) are
set to 100%, and error bars represent standard deviation. Asterisk represents values outside of the control range.
D, E Confirmatory Sanger sequencing to show each parent was heterozygous for a single OXA1L variant. Asterisk indicates position of the labelled variant.
F Analysis of mRNA from the patient by RT–PCR showed that the c.620G>T variant affects splicing and can lead to skipping of exon 4 (p.(Cys207_Glu2545del)) or the
p.Cys207Phe amino acid substitution.
G Evolutionary conservation of OXA1L human Cys207 residue (blue box).
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neuronal cell loss from the dentate nucleus and intact expression of
NDUFS3, NDUFB8, SDHA, COXI and ATP5B.
OXPHOS steady-state levels and complex assembly in fibroblasts
and skeletal muscle
Western blot analysis of patient fibroblasts and skeletal muscle
was carried out to assess the steady-state levels of OXA1L and
OXPHOS components. OXA1L protein levels were decreased both
in patient fibroblasts (Fig 2A) and in skeletal muscle (Fig 2B)
compared to controls demonstrating a functional consequence of
the identified OXA1L variants. Interestingly, there was no observ-
able difference in the size of the OXA1L protein in the patient
sample, suggesting that the protein missing exon 4 is either not
produced or rapidly degraded. This would infer that the residual
levels of OXA1L in the patient are likely to be the variant carrying
the p.(Cys207Phe) amino acid substitution only. Western blot
assessment of subunits of the OXPHOS complexes showed a
decrease of the mtDNA-encoded complex IV subunits (COXI and
COXII) both in fibroblasts (Fig 2A) and in skeletal muscle
(Fig 2B), which is consistent with the deficiency in complex IV
activity in skeletal muscle (Fig 1C) and strongly supports a role of
OXA1L in the assembly of complex IV. Patient fibroblasts (Fig 2A)
and skeletal muscle (Fig 2B) also showed a decrease in the steady-
state levels of complex V subunit ATP5B and a slight decrease in
the complex I subunit NDUFB8 on Western blots, consistent with
previously reported complex V and complex I defects in OXA1L-
depleted HEK293 cells (Stiburek et al, 2007). Furthermore,
complexes I, IV and V assembly defects were observed in patient
fibroblasts (Fig 2C) and skeletal muscle (Fig 2D) when assessed
by Blue Native PAGE. There appear to be some tissue-specific dif-
ferences, for example, the levels of fully assembled complex I
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Figure 2. OXPHOS complex steady-state levels and assembly analysis in patient tissues.
A Western blot analysis of OXA1L and OXPHOS complex subunits in patient (P) and control (C1, C2) fibroblasts using VDAC1 and b-actin as loading controls.
B Western blot analysis of OXA1L and OXPHOS complex subunits in patient and control skeletal muscle. Complex II subunits SDHA and SDHB were used as loading controls.
C Analysis of respiratory complex assembly by Blue Native PAGE in patient fibroblasts solubilised using DDM as a detergent. Antibodies against NDUFB8 (CI), SDHA (CII),
UQCRC2 (CIII), COXI (CIV) and ATP5A (CV) were used. * denotes subassembly complex.
D Analysis of respiratory complex assembly by Blue Native PAGE in patient skeletal muscle from the diaphragm (Pdia) and quadriceps (Pquad). Muscle mitochondrial
extracts were solubilised using DDM, and antibodies against NDUFB8 (CI), SDHA (CII), UQCRC2 (CIII), COXI (CIV) and ATP5A (CV) were used to detect each complex.
E Western blot analysis of control fibroblasts (C1, C2), patient fibroblasts (P), patient fibroblasts mock transduced with retroviral vector (P+Mock) and patient fibroblasts
transduced with retroviral vector containing wild-type human OXA1L (P+OXA1L). Alpha tubulin was used as a loading control.
F Activities of mitochondrial respiratory complexes I (CI), III (CIII) and IV (CIV), normalised to complex II (CII), in control fibroblasts (white), patient fibroblasts (black) and
patient fibroblasts transduced with wild-type human OXA1L (grey). Mean enzyme activities of control fibroblasts (n = 11) are set to 100%, and error bars represent
standard deviation.
Source data are available online for this figure.
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(980 kDa) was markedly lower in patient fibroblasts compared to
controls, but there is an increase in a subassembly complex
(Fig 2C). This subassembly intermediate is not present in skeletal
muscle, and the decrease in fully assembled complex I in patient
skeletal muscle is much less pronounced than in fibroblasts
(Fig 2D). In contrast, the assembly of complex IV is markedly
decreased both in fibroblasts (Fig 2C) and in skeletal muscle
(Fig 2D) and is consistent with the seemingly isolated complex IV
deficiency initially seen in skeletal muscle (Fig 1C).
Retroviral transfection of patient fibroblasts with wild-type
OXA1L rescues the OXPHOS defect
In order to confirm that the identified variants in OXA1L were
pathogenic in the patient, we cloned the full-length human OXA1L
cDNA into a retroviral vector and transduced patient fibroblasts.
After viral transduction, OXA1L protein levels in patient fibroblasts
increased to levels similar to endogenous OXA1L in control fibro-
blasts (Fig 2E). Steady-state levels of complex IV and complex V
subunits were also increased to control levels by the introduction of
wild-type OXA1L into patient fibroblasts (Fig 2E). Activities of respi-
ratory complexes were also assessed in patient fibroblasts, showing
an increase in complex IV activity in patient fibroblasts transduced
with wild-type OXA1L (Fig 2F). These data demonstrate that the
OXPHOS defects seen in patient fibroblasts were caused by the
OXA1L variants, confirming pathogenicity.
OXA1L depletion leads to a combined OXPHOS defect, including
loss of complex IV
Since we observed tissue-specific OXPHOS defects—i.e. a more
prominent complex IV defect in skeletal muscle, a seemingly
isolated CI deficiency in brain tissue and a combined respiratory
deficiency in fibroblasts—we further investigated the importance of
OXA1L by a variety of independent means.
Firstly, OXA1L was depleted in Drosophila to assess potential
effects on OXPHOS complexes using an RNAi construct against the
predicted OXA1L Drosophila orthologue gene: CG6404. Depletion of
CG6404 was confirmed at the mRNA level by qPCR (Fig 3A) as the
human OXA1L antibody did not recognise the fly orthologue, and
there is no antibody against the fly protein. Steady-state levels of
representative subunits from all OXPHOS complexes were decreased
in OXA1L-depleted flies (whole fly lysates) compared to controls,
with complex I (NDUFS3) being the most affected (Fig 3B).
However, porin levels were not different between mutant and
control flies indicating that CG6404-depleted flies do not have less
mitochondrial mass (Fig 3B). OXPHOS deficiency was confirmed by
high-resolution respirometry that, as expected, showed a marked
reduction of oxygen consumption in OXA1L-IR flies (Fig EV4).
Secondly, we investigated the effects of artificially reducing
OXA1L in human cell lines (U2OS) using siRNA. A combined Smart-
Pool of four different OXA1L siRNAs led to efficient depletion of
OXA1L and markedly decreased the steady-state levels of complex
IV subunit COXII, demonstrating a clear complex IV defect in U2OS
cells depleted of OXA1L (Fig 3C). Furthermore, the levels of several
mitoribosomal proteins (MRPs) were also decreased in the OXA1L-
depleted cells (Fig 3C). The same observations were made when
using two of the OXA1L siRNAs in isolation, with levels of COXII,
MRPL45 and MRPS26 decreasing in line with levels of OXA1L
protein (Fig 3D).
In a final approach, we sought to knockout the expression of
OXA1L in HEK293T cells using CRISPR/Cas9. Following a number of
attempts using different guide RNAs (gRNAs), we were unable to
identify clones with a complete disruption in all OXA1L alleles. This
is consistent with OXA1L being found to be an essential fitness gene
in a genome-wide CRISPR screen (Hart et al, 2015). We therefore
undertook an approach previously used to deplete an essential gene
(Stroud et al, 2016). We generated expression constructs harbouring
silent base-pair changes in the OXA1L cDNA allowing the amino
acids sequence to remain unchanged but that would block both bind-
ing of the gRNAs and cutting by our CRISPR/Cas9 constructs. Two
variants were made for separate gRNA targets. Both variants were
cloned into a lentiviral expression vector with a C-terminal FLAG tag
downstream of a doxycycline-inducible promoter, before stable
transduction into HEK293T cells. These cells were then subjected to
targeting of the OXA1L genomic alleles using the appropriate
CRISPR/Cas9 construct in the presence of doxycycline. Single cells
were sorted and analysed for loss of endogenous OXA1L by
immunoblotting. Two cell lines, from different gRNA targeting
approaches (termed OXA1L-1 and OXA1L-2), were selected and
subsequently characterised. Cells incubated with increasing levels of
doxycycline were assessed for OXA1L-FLAG expression by Western
blot analysis (Fig 3E). Doxycycline was subsequently used at
concentrations of 10 or 20 ng/ml for OXA1L-1 and OXA1L-2, respec-
tively. Cells cultured in the absence of doxycycline succumbed after
7 days, suggesting expression of OXA1L is essential for cell viability
(data not shown). Next, cells were incubated in the absence or pres-
ence of doxycycline for 5 days before mitochondria were isolated
and analysed by BN-PAGE for changes in the levels of OXPHOS
complexes harbouring mtDNA-encoded subunits (Fig 3F). As can be
seen, depletion of OXA1L led to clear and substantial loss in OXPHOS
complexes I, III, IV and V. In addition, loss of OXA1L also led to
decreased levels of mitoribosomal subunits (Fig 3G), consistent with
OXA1L depletions using siRNA in U2OS cells (Fig 3C and D).
OXA1L-FLAG immunoprecipitation enriches mtDNA-encoded
proteins and assembly factors of complexes I and IV
Next, we asked what proteins associate in complexes with OXA1L.
Mitochondria from OXA1L-1 cells cultured in the presence of doxy-
cycline were solubilised in digitonin before affinity enrichment of
OXA1L-FLAG using anti-FLAG beads. Bound material was eluted
with FLAG peptide and subjected to quantitative mass spectrometry
and compared against control HEK293T cells subjected to the same
treatment. As seen in Fig 4A, nine of the 13 mtDNA-encoded sub-
units from complexes I, IV and V were enriched with OXA1L-FLAG.
Many nuclear-encoded subunits together with known assembly
factors were also detected (Dataset EV1), indicating that assembly
intermediates may be assembled during the insertion of core sub-
units into the inner membrane.
Assessment of mitochondrial translation and mitoribosomal
proteins in patient fibroblasts
As several MRPs were decreased in our siRNA and CRISPR
OXA1L knockdowns, we next assessed mitochondrial protein
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synthesis in patient fibroblasts. Western blotting analysis revealed
no change in the steady-state protein levels of MRPL3, MRPL11,
MRPL45 or MRPS26 in patient fibroblasts compared to control
(Fig 4B). The stability of the mitoribosome in patient fibroblasts
may be explained by the higher residual levels of OXA1L (approx-
imately 30% relative to control fibroblasts) than in either of the
knockdown experiments, where residual OXA1L levels are much
lower. To assess de novo mitochondrial protein synthesis in
human fibroblasts, cells were incubated with media lacking
methionine and cysteine while concomitantly inhibiting cytosolic
translation with emetine dihydrochloride. Cells were then incu-
bated with [35S] labelled methionine and cysteine for 1 h (pulse)
followed by either a 4-h or 8-h period with normal growth media
containing methionine (chase). There was no clear difference in
de novo mitochondrial protein synthesis between control and
patient fibroblasts in the 1 h pulse, but after 8 h chase, there was
a marked decrease in signal from the newly synthesised
mitochondrial proteins in the patient fibroblasts (Fig 4C). These
data suggest that the mitoribosomes are translating efficiently in
patient fibroblasts, but that the nascent polypeptides are less
stable and degrade more rapidly than in control cells. These data
are consistent with the role of OXA1L in the co-translational
insertion of mtDNA-encoded proteins into the IMM (Szyrach et al,
2003; Haque et al, 2010).
Discussion
Here, we describe a case of mitochondrial disease caused by muta-
tions in OXA1L, which leads to a severe encephalopathy, hypotonia
and developmental delay. We have established the pathogenicity of
these variants by showing rescue of the CI, CIV and CV defects in
patient fibroblasts after introducing wild-type OXA1L via a retroviral
vector (Fig 2E).
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Figure 3. Analysis of OXA1L depletion in D. Melanogaster and human cells with siRNA and CRISPR/Cas9.
A CG6404 mRNA level in control (black and grey) and OXA1L siRNA-treated flies (red) normalised to RpL32 mRNA with control 1 (black) set to 1. Four biological
replicates per group. One-way ANOVA with Tukey’s multiple comparison test. Error bars represent standard error of the mean (SEM). **** denotes P < 0.0001.
B Western blot analysis of OXPHOS complex subunits in fly homogenates from control (Ctrl 1, Ctrl 2) and CG6404 siRNA-depleted (OXA1L-IR) flies. Three biological
replicates per group. One-way ANOVA with Tukey’s multiple comparison test.
C Representative figure of Western blot analysis performed on cell lysate (30 lg) after 6 days of incubation with either NT-siRNA or OXA1L SmartPool siRNA. The
steady-state level of OXA1L and of components of the mt-LSU (MRPL45, MRPL11) and mt-SSU (MRPS26, MRPS22) were evaluated, as well as the steady-state level of
the mtDNA-encoded protein COXII. SDHA and TOM20 antibodies were used as loading controls.
D Western blot analysis was performed on cell lysate (30 lg). The efficiency of the depletion was assessed with antibodies targeting OXA1L. Steady-state levels of the
mt-encoded protein COXII as well as mitoribosomal proteins MRPL45 and MRPS26 were also visualised. The equality of the loading was controlled using antibodies
targeting b-actin. The figures are representative of two biological repeats. The dashed line indicates that some lanes were omitted from the figure.
E Two independent cell lines (OXA1L-1 and OXA1L-2) were grown in different concentrations of doxycycline (DOX) to modulate OXA1LFLAG expression. Mitochondria
were isolated and compared with control mitochondrial from wild-type HEK293T cells (labelled C) by SDS–PAGE and immunoblotting with antibodies against OXA1L,
FLAG epitope and TOM20 (as control).
F Mitochondria were isolated from cells treated with or without 10 ng/ml DOX for 5 days. Samples were solubilised in digitonin before BN-PAGE analysis of
supercomplex forms of respiratory complex I (NDUFA9), complex III (UQCRC1), complex IV (COXIV) and complex V (ATP5A) by immunoblotting.
G Ribosomal subunits were analysed by SDS–PAGE and immunoblotting. Blots stained with Coomassie brilliant blue (CBB) serve a loading controls.
Source data are available online for this figure.
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Interestingly, initial diagnostic tests showed a seemingly isolated
complex IV deficiency in patient skeletal muscle, prompting the
sequencing of several COX assembly genes. However, subsequent
neuropathology experiments indicated an isolated complex I defi-
ciency in the central nervous system. It is also worth noting that
while patient skeletal muscle initially appeared to show an isolated
complex IV deficiency in terms of activity (Fig 1C), Western blotting
and BN-PAGE showed a clear complex V defect (which was not
assessed by enzymatic assay) and milder defects in complex I
(Fig 2C and D) in addition to the complex IV defect. The tissue-
specific effects of the OXA1L variants remain unexplained, but
perhaps suggest that the mitochondrial insertase machinery can
vary between tissues, possibly due to differential expression of
OXA1L isoforms or that other, as yet unidentified, insertases present
in human mitochondria can substitute for OXA1L in different
tissues. Interestingly, available mRNA expression data for OXA1L
suggest that brain tissue has the lowest relative expression of
OXA1L and that the expression pattern is fairly similar between the
various isoforms (Fig EV5). Recently, more distant homologues of
Oxa1 have been identified in the eukaryotic endoplasmic reticulum,
namely the DUF106-related proteins WRB/Get1, EMC3 and TMCO1
(Anghel et al, 2017). Similar phylogenetic analysis yielded the same
list of homologues with no additional insertase candidates
(Appendix Fig S1 and Appendix Table S2).
To our knowledge, the only previous report of OXA1L function
in humans was conducted with shRNA depletions in HEK293 cells
(Stiburek et al, 2007) and demonstrated clear defects in complexes I
and V, but complex IV remained unchanged. This was surprising as
OXA1L was initially identified as a human gene involved in complex
IV assembly through its functional complementation of a complex
IV defect in Oxa1p knockout yeast strains (Bonnefoy et al, 1994b).
We saw a similar sparing of complex IV in the brain tissue of the
patient, with only an isolated complex I defect detected through
neuropathology studies (Figs EV2 and EV3), but patient fibroblasts
and skeletal muscle showed clear complex IV defects. We sought to
corroborate our findings in patient tissues and to demonstrate the
effects of OXA1L depletion on complex IV assembly by other means.
We saw clear defects in complex IV, as well as complexes I and V
when OXA1L was depleted using: (i) siRNA in D. melanogaster
(Fig 3B), (ii) siRNA in human U2OS lines (Fig 3C), and (iii)
CRISPR/Cas9 in HEK293T cells (Fig 3F). Taken together, these data
demonstrate that OXA1L is indeed important for complex IV assem-
bly in many human cell types and can act as a general insertase
for the majority of mtDNA-encoded subunits into the inner mito-
chondrial membrane. Similarly, we observed that all respiratory
complexes including complex IV were affected by depletion of
CG6404 (the fly orthologue of OXA1L) in Drosophila. Mitochondrial
respiration was strongly affected (Fig EV4) and flies died shortly (1
or 2 days) after eclosion. These data support an essential role for
OXA1L in the assembly of respiratory complexes that have been
conserved during evolution.
Immunoprecipitation experiments showed that OXA1L-FLAG
interacts with at least nine of 13 mtDNA-encoded proteins along
with many nuclear-encoded subunits and assembly factors of
complexes I, III, IV and V (Fig 4A, Dataset EV1), suggesting OXA1L
may have a role in assembly of these complexes around the co-
translational insertion of the core subunits. We have also shown
that mitochondrial protein synthesis is not affected in patient
A B
C
Figure 4. Identifying interacting partners of OXA1L and assessing
mitochondrial protein synthesis in patient fibroblasts.
A Affinity purification mass spectrometry analysis of proteins interacting with
OXA1L-FLAG. Control (HEK293T) or OXA1L-1 cells expressing OXA1L-FLAG were
solubilised in 1% (w/v) digitonin and incubated with anti-FLAG affinity gel
(n = 3). Eluates were analysed by label-free quantitative mass spectrometry
(LFQ). Log2 LFQ intensities were submitted to a modified two-sided two-
sample t-test with significance determined through permutation-based false
discovery rate (FDR) statistics as described in the Materials and Methods.
Enriched respiratory complex subunits are colour-coded, and mtDNA-
encoded subunits are labelled. Full data are provided in Dataset EV1.
B Western blot analysis was performed from control (C) and OXA1L patient
immortalised fibroblasts (P). The steady-state level of OXA1L was assessed as
were the steady-state levels of components of the OXPHOS system (NDUFB8,
COXII and ATP5b). On a separate Western blot, the levels of the mitoribosomal
proteins MRPL3, MRPL45, MRPL11 and MRPS26 were detected. For both the
membranes, b-actin was used as loading control. The dashed line indicates
that some lanes were omitted from the figure.
C Control (C1) and patient (P) fibroblasts were treated with emetine
dihydrochloride to inhibit cytosolic translation and mitochondrial protein
synthesis analysed by [35S] Met/Cys incorporation with 1 h pulse and either
4 or 8 h chase. Cell lysate (50 lg) was separated through a 15%
polyacrylamide gel. The gel was stained with Coomassie blue (CBB) to
confirm equal loading. After fixation and drying the signal was visualised
using a Typhoon FLA9500 PhosphorImager. Signals were ascribed following
established migration patterns (Chomyn, 1996).
Source data are available online for this figure.
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fibroblasts, but that the stability of nascent polypeptides is
decreased, which is also consistent with a role for OXA1L in co-
translational insertion and respiratory complex assembly.
In both siRNA and CRISPR/Cas9 OXA1L knockdown experi-
ments, there was a loss of mitoribosomal proteins (Fig 3C, D and G),
which may be a secondary effect of severe OXA1L depletion since
the patient cells with a milder OXA1L depletion do not show loss of
MRPs or impaired mitochondrial translation (Fig 4B and C). It is
likely that the extreme knockdown of OXA1L is causing loss of MRPs
as a downstream secondary effect, possibly due to problems with
the mitochondrial membrane potential and/or protein import. This
is consistent with the fact that several members of the protein import
machinery and certain mitochondrial carriers were also shown to
interact with OXA1L in the OXA1L-FLAG immunoprecipitation
experiments (Dataset EV1). Problems with protein import would
also account for the decreased SDHA seen in OXA1L-depleted flies
(Fig 3B). In yeast, Oxa1p has been shown to be required for the
biogenesis of the Tim18-Sdh3 module of the TIM22 complex (Stiller
et al, 2016), which is responsible for the import of many inner
membrane proteins. This demonstrates that, in yeast, Oxa1p plays a
major role in the biogenesis of other inner membrane proteins as a
secondary consequence of impaired protein import in Oxa1-deficient
mitochondria. The fact that MRP levels are not affected in the patient
suggests that the primary effects of OXA1L are in the co-translational
insertion of mtDNA-encoded proteins and OXPHOS complex assem-
bly. It is likely that complete loss-of-function mutations are not seen
in patients due to more severe mutations not being compatible with
life, which is supported by the CRISPR/Cas9 OXA1L knockouts only
surviving for 7 days without doxycycline treatment and the death of
OXA1L-depleted flies shortly after eclosion.
In yeast, Oxa1p has long been known to be required for the
correct insertion of several mtDNA-encoded subunits (Hell et al,
1997, 2001; Jia et al, 2007). Furthermore, Oxa1p plays a crucial
role in N-tail protein export in mitochondria, where the N-terminal
tail of inner membrane proteins is translocated from the mitochon-
drial matrix to the intermembrane space (Hell et al, 1998). This
process applies to nuclear-encoded mitochondrial inner membrane
proteins that are imported to the matrix and also to some of the
mtDNA-encoded proteins that require the N-terminal tail to reside
on the intermembrane space side of the membrane, such as
Cox2p. The C-terminal tail of Cox2p is also translocated across the
membrane to the intermembrane space, and this process is also
impaired in yeast strains lacking Oxa1p (He & Fox, 1997). Another
member of the Oxa1 insertase family, Cox18p, is also essential for
the translocation of the C-terminal tail of Cox2p in yeast (Saracco
& Fox, 2002). Recently, it has been shown that knockout of COX18
(the human homologue of Cox18p) using TALENs impairs the
translocation of the C-terminal tail of COXII in human cell lines
(Bourens & Barrientos, 2017). This demonstrates a strong func-
tional conservation in the insertion of COXII between yeast and
humans. Knockout of COX18 had no effect on the N-terminal
insertion of COXII, suggesting other insertases are involved in this
process. Since Oxa1p is essential for N-terminal insertion of Cox2p
in yeast (Hell et al, 1998) and the homologues Cox18p and COX18
are functional orthologs, it is likely that OXA1L is at least partially
responsible for N-terminal insertion of COXII in humans. Our data
are consistent with this notion as COXII is decreased in patient
fibroblasts (Fig 2A), skeletal muscle (Fig 2B) and OXA1L
siRNA-depleted U2OS cells (Fig 3D), and COXII was significantly
enriched in the OXA1L-FLAG immunoprecipitation experiments
(Fig 4A). OXA1L is not only important for COXII insertion, but is
more likely to be a more generalised insertase similarly to Oxa1p
in yeast (Hell et al, 2001).
In summary, our data confirm the pathogenicity of the
c.500_507dup, p.(Ser170Glnfs*18) and c.620G>T, p.(Cys207Phe)
OXA1L variants and demonstrate a role for OXA1L in the co-transla-
tional insertion/assembly of OXPHOS complexes I, IV and V.
Materials and Methods
Neuropathology
Postmortem CNS tissues were taken from a 5-year-old male and
were fixed in formalin for 21 days and paraffin-embedded before
undergoing routine neuropathological examination. In order to
document the severity of the pathological changes in patient tissues,
CNS tissues from two non-neurologically affected controls were
obtained from the Edinburgh Brain and Tissue Bank. Histology was
performed as previously described (Lax et al, 2012).
Whole exome sequencing
Whole exome sequencing was undertaken using an Illumina
paired-end pre-capture library and hybridised to the HGSC CORE
exome capture design (52 Mb, NimbleGen) and subsequently
sequenced on a HiSeq 2500 to an average 100× average coverage.
Bioinformatic analyses were conducted as previously described
(Stiles et al, 2015). Single nucleotide variants (SNVs) and small
insertions and deletions (InDels) were scored by GATK (DePristo
et al, 2011). Quality control filtering of variants was based on
coverage, strand bias, mapping quality and base quality. Custom
Perl scripts were used to annotate variants as previously described
(Bonnen et al, 2013; Stiles et al, 2015). Algorithms used for
prediction of potential functional consequences of variants
included CADD (Kircher et al, 2014), SIFT (Ng & Henikoff, 2002)
and PolyPhen2 (Adzhubei et al, 2013), Genomic Evolutionary Rate
Profiling (GERP; Davydov et al, 2010), and PhyloP (Cooper et al,
2005).
Generation of the OXA1L depletion line
HEK293T cells were cultured in DMEM supplemented with 10%
FBS, penicillin/streptomycin and 50 lg/ml uridine (Sigma). Genera-
tion of OXA1L-inducible knockout cell lines was performed by
disrupting the genomic OXA1L copies and inserting OXA1L into cells
under a doxycycline-inducible promoter as previously described for
NDUFAB1 (Stroud et al, 2016). Briefly, two different doxycycline-
inducible OXA1L constructs containing silent mutations to either
destroy the PAM site or block gRNA recognition along with a C-
terminal FLAG epitope (referred to as OXA1L-FLAG) were cloned
into the pLVX-TetOne-Puro plasmid (Clontech) and transduced
into clonal HEK293T cells using lentivirus particles. Oxa1L-1
CRISPR/Cas9 targeted exon 2 using the guide sequence 50-
GCGAGGGCCCTGCGACGCTG-30 and the cDNA stably transduced
harboured the silent mutation c.60 C > G to mutate the PAM site.
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Oxa1L-2 targeted exon 3 using the guide sequence 50-
GATCTGGGCCTACCTTGGTG-30 and the cDNA stably transduced
harboured the silent mutations (50-GACCTCGGGTTGCCATGGTG-30)
to mutate the gRNA-binding site (as the PAM site could not be
mutated in this case). Cells were grown in the presence of 2 lg/ml
puromycin for 72 h to select transduced cells, and expression of
OXA1L-FLAG was confirmed after expression with 1 lg/ml doxycy-
cline (DOX; Clontech) for a further 72 h, followed by SDS–PAGE
and immunoblotting with OXA1L (Proteintech) or FLAG (Sigma-
Aldrich) antibodies. Once OXA1L-FLAG expression was confirmed,
cells were grown in the presence of 50 ng/ml DOX and then trans-
fected with pSpCas9(BB)-2A-GFP (Addgene 48138, a gift from F.
Zhang; Ran et al, 2013) encoding the appropriate gRNA sequence.
Cells were single-cell FACS-sorted, and clones were selected based
on loss of endogenous OXA1L. Cells were maintained in the pres-
ence of 50 ng/ml DOX with media being changed every 48 h. Loss
of endogenous OXA1L was confirmed by performing Western blot-
ting of cell extracts and immunodecoration with OXA1L antibodies
and sequencing of alleles for indels. Doxycycline concentrations
were titrated to match expression levels with endogenous OXA1L in
control cells.
Analysis of human OXA1L depletion
For OXA1L depletion experiments, cells were cultured in DMEM
containing 10% dialysed FBS (Sigma) and grown for 5 days in the
presence or absence of 10 ng/ml DOX. Mitochondria were isolated
and proteins and their complexes analysed by BN-PAGE as previ-
ously described (Formosa et al, 2015) and NuPAGE SDS–PAGE
(Thermo Fisher).
Affinity purification mass spectrometry (AP-MS)
Affinity purification mass spectrometry was performed using whole
cell lysates. For affinity purification, control HEK293T and OXA1L-
FLAG cells (3 mg total protein) were resuspended in triplicate in
500 ll AP buffer (20 mM Bis-Tris pH 7, 50 mM NaCl, 10% (v/v)
glycerol) containing 1% digitonin and incubated for 30 min on ice.
Insoluble material was removed by centrifugation at 21,000 g, and
the supernatant was incubated with 30 ll anti-FLAG M2 affinity gel
(Sigma) for 1 h with rotation at 4°C. Beads were washed 10 times
with AP buffer containing 0.1% (w/v) digitonin and finally eluted
with 200 ll of AP buffer containing 150 lg/ml FLAG peptide
(Sigma).
For mass spectrometry, proteins were acetone precipitated,
reduced, alkylated, trypsin digested and desalted as previously
described (Stroud et al, 2016). Peptides were reconstituted in 0.1%
(v/v) trifluoroacetic acid (TFA) and 2% (v/v) acetonitrile (ACN)
and analysed by online nano-HPLC/electrospray ionisation-MS/MS
on a Q Exactive Plus connected to an Ultimate 3000 HPLC (Thermo
Fisher Scientific). Peptides were loaded onto a trap column
(Acclaim C18 PepMap nano-Trap × 2 cm, 100 lm I.D, 5 lm
particle size and 300 A˚ pore size; Thermo Fisher Scientific) at
15 ll/min for 3 min before switching the pre-column in line with
the analytical column (Acclaim RSLC C18 PepMap Acclaim RSLC
nanocolumn 75 lm × 50 cm, PepMap100 C18, 3 lm particle size
100 A˚ pore size; Thermo Fisher Scientific). The separation of
peptides was performed at 250 nl/min using a linear ACN gradient
of buffer A [0.1% (v/v) formic acid, 2% (v/v) ACN] and buffer B
[0.1% (v/v) formic acid, 80% (v/v) ACN], starting at 12.5% buffer
B to 38.5% followed by ramp to 99% over 30 min. Data were
collected in positive mode using data-dependent acquisition using
m/z 375–1,800 as MS scan range, HCD for MS/MS of the 12 most
intense ions with z ≥ 2. Other instrument parameters were as
follows: MS1 scan at 70,000 resolution (at 200 m/z), MS maximum
injection time 50 ms, AGC target 3E6, normalised collision energy
was at 27% energy, isolation window of 1.8 Da, MS/MS resolution
17,500, MS/MS AGC target of 1E5, MS/MS maximum injection time
100 ms, minimum intensity was set at 1E3 and dynamic exclusion
was set to 20 s. Raw files were analysed using the MaxQuant plat-
form (Tyanova et al, 2016a) version 1.6.0.1 searching against the
UniProt human database containing reviewed, canonical and
isoform variants in FASTA format (June 2016) and a database
containing common contaminants. Default search parameters for a
label-free (LFQ) experiment were used with modifications. Briefly,
multiplicity was set to 1 (unlabelled), and “LFQ”, “Re-quantify”
and “Match between runs” were enabled with default settings.
Unique and razor peptides were used for quantification, using a
LFQ minimum ratio count of 1. Using the Perseus platform
(Tyanova et al, 2016b) version 1.5.5.3, proteins identified from < 2
MS/MS were excluded, along with those lacking LFQ intensity
values for all three OXA1LFLAG experiments. Missing values for
control (HEK293T) experiments were imputed to values based on
the distribution of LFQ intensity values in each column, with
downshift of 2.2 and width of 0.3. These values were empirically
determined to place imputed values on the tail end of intensity
distribution. A modified two-sided t-test based on permutation-
based FDR statistics (Tyanova et al, 2016b) was performed
between experimental groups, and the negative logarithmic
P-values were plotted against the differences between the Log2
means for the two groups. A significance threshold (FDR < 0.01,
s0 = 8) was determined that excludes all values on the left (con-
trol) side of the test. Raw data, including q-values used for indicat-
ing significance, can be found in Dataset EV1.
Fly husbandry
Drosophila melanogaster flies were maintained at 25°C for all
experiments. Flies were cultured on standard media (1% agar,
1.5% sucrose, 3% glucose, 3.5% dried yeast, 1.5% maize, 1%
wheat, 1% soya, 3% treacle, 0.5% propionic acid, 0.1% Nipagin)
with a controlled 12 h:12 h light:dark cycle. A line carrying a
UAS-RNAi construct against CG6404 was obtained from the Vienna
Drosophila Resource Center (ID: 108091). The Tubulin-GeneSwitch
(tubGS) driver was a generous gift from the laboratory of Dr Scott
Pletcher, and virgin females carrying the tubGS driver (back-
crossed into our Dahomey control background for six generations)
were crossed with (i) males carrying the RNAi construct against
CG6404 or (ii) males from the VDRC control stock w1118 to control
for the effects of the driver (this group is named Ctrl1 in figures).
Additionally, Dahomey virgin females were crossed with males
carrying the UAS-RNAi construct against CG6404 (this group is
named Ctrl2 in figures) to control for positional effects of the RNAi
construct insertion. Males were collected following eclosion and
transferred to new food for one day before being used for
experiments.
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Western blot analysis—Drosophila
Sample preparation (20 flies were used per sample, three biological
replicates per group) and Western blotting were performed as
described in Scialo` et al (2016). The primary antibodies employed
together with the appropriate secondary antibodies were as follows:
anti-NDUFS3 (Abcam; ab14711) 1:1,000 diluted in 5% milk in PBS-
Tween 1x, anti-SDHA (Abcam; ab209986) 1:500 diluted in 5% BSA
in PBS-Tween 1x; anti-ATP5a (Abcam; ab14748) 1:100,000 diluted
in 5% milk in PBS-Tween 1x, anti-UQCRC1 (Abcam; ab110252)
1:500 diluted in 5% BSA in PBS-Tween 1x, anti-MTCO1 (Abcam;
ab14705) 1:500 diluted in 5% BSA in PBS-Tween 1x, Porin (Abcam;
ab14734) 1:1,000 diluted in 5% milk in PBS-Tween 1x, anti-beta-
tubulin [EPR16774] (Abcam; ab179513) 1:1,000 diluted in 5% milk
in PBS-Tween 1x, HRP Horse Anti-Mouse IgG Antibody (Peroxidase;
Vector laboratories, California; PI-2000) 1:5,000 diluted in 5% milk,
HRP Goat Anti-Rabbit IgG Antibody (Peroxidase; Vector laborato-
ries, California; PI-1000) 1:5,000 diluted in 5% milk. Image quan-
tification: ImageJ was used to quantify the protein band intensities.
For each image, the bands were quantified and normalised by the
corresponding tubulin intensity used as a loading control.
High-resolution respirometry—Drosophila
O2 consumption was measured in homogenates from whole male
flies as described previously (Scialo` et al, 2016). Briefly, 20 flies
were homogenised in assay buffer (120 mM KCl, 5 mM KH2PO4,
3 mM Hepes, 1 mM EGTA, 1 mM MgCl2, 0.2%, pH 7.2) and incu-
bated in the same buffer containing 0.2% bovine serum albumin at
25°C. Respiration was measured by using an Oroboros O2K
(Oroboros Instruments Corp) using specific substrates and inhibitors
for complex I (pyruvate/proline and rotenone), complex III (glyc-
erol-3-phosphate, antimycin A) and complex IV (ascobarte/TMPD
(N,N,N0,N0-tetramethyl-p-phenylenediamine), cyanide). Values were
normalised by citrate synthase activity measured as described previ-
ously (Magwere et al, 2006). ANOVA test was followed by Tukey’s
multiple comparisons test. Normality of samples was tested using
Shapiro–Wilk test, and Bartlett’s test was used to assess
homoscedasticity.
RNA extraction, cDNA synthesis and qPCR—Drosophila
RNA extraction was performed as described previously (Scialo` et al,
2016). Twenty flies were used per sample, four biological replicates
per group. cDNA synthesis: cDNA synthesis was carried out using
the High-Capacity cDNA Reverse Transcription Kit (Fisher Scientific,
Applied BiosystemsTM; 4368814). qPCR: qPCR was carried out using
SYBR green SensiFast Hi-Rox buffer (Bioline: BIO-92020), and the
following primers for CG6404 (forward primer: AGCCCTGCCC
ATTGTTATCT, reverse: primer CTTCTTAGGTGGCAGTGCAC) were
used. RpL32 was used as internal standard (forward primer:
AGGCCCAAGATCGTGAAGAA, reverse primer: TGTGCACCAGG
AACTTCTTGAA).
Retroviral rescue
The full-length human OXA1L cDNA (mammalian genome collec-
tion clone BC001669) was amplified by PCR (KAPA HiFi), cloned
into pDONR 201 with BR Clonase II (Thermo Fisher) and subse-
quently cloned into the Gateway converted retroviral vector pBABE-
puro with LR Clonase II. Retrovirus was generated by transient
transfection of retroviral plasmids into the Phoenix amphotropic
packaging line. Transduced fibroblasts were used directly in experi-
ments following selection with puromycin.
Muscle histology and biochemistry
Informed consent for diagnostic and research-based studies was
obtained from the family in accordance with the Declaration of
Helsinki protocols and approved by local institutional review
boards. Histological and histochemical analyses were performed on
10 lm transversely orientated serial cryosections of a skeletal
muscle biopsy sample using standard procedures. The activities of
The paper explained
Problem
Mitochondrial diseases are a group of disorders characterised by mito-
chondrial dysfunction, predominantly resulting in decreased energy
production in the form of ATP made by the oxidative phosphorylation
(OXPHOS) system. Mitochondrial diseases are very varied, in terms of
both their clinical manifestations and their genetic causes. They can
be caused by mutations within the mitochondrial genome itself
(mtDNA) or mutations in nuclear genes that encode mitochondrial
proteins (1,200). More than 300 of these genes have been associated
with mitochondrial disease, and this diversity often makes obtaining
genetic diagnoses in patients with mitochondrial disease difficult.
OXA1L is a mitochondrial protein encoded by the nuclear genome and
belongs to the YidC/Alb3/Oxa1 membrane protein insertase family.
Oxa1 in yeast is known to be important for the insertion and assem-
bly of subunits of OXHPOS complex IV, but in human cells, OXA1L
depletion has been reported to cause defects in complexes I and V
only. There have not been any previous reports of OXA1L mutations in
mitochondrial disease patients.
Results
We used whole exome sequencing to identify recessively inherited
variants in OXA1L (NM_005015.3; c.500_507dup, p.(Ser170Glnfs*18)
and c.620G>T, p.(Cys207Phe) in a patient with a mitochondrial disor-
der, presenting at birth with hypotonia, severe encephalopathy and
developmental delay. We showed that OXPHOS complexes I, IV and V
were impaired in patient samples with a particularly notable
biochemical deficiency of complex IV in skeletal muscle. We also
demonstrated a combined OXPHOS defect (including complex IV) with
targeted depletion of OXA1L in human cell lines and in a Drosophila
model. Critically, we confirmed the OXA1L variants are causative of
the disease in the patient by showing a rescue the OXPHOS defect in
patient fibroblasts following the retroviral delivery of a wild-type (nor-
mal) copy of OXA1L.
Impact
Our study documents the first case of mitochondrial disease caused
by mutations in OXA1L. Confirmation of these mutations as causative
in this case allowed pre-natal testing of a subsequent pregnancy in
this family, demonstrating the clinical importance of providing a
genetic diagnosis in mitochondrial disease cases. OXA1L may now be
screened as a candidate gene in future cases with a similar clinical
presentation. Our work also provides clearer insight into the function
of OXA1L, given we have shown that OXA1L not only affects
complexes I and V, but is also important for the correct assembly and
function of complex IV in humans.
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individual respiratory chain complexes and citrate synthase, a mito-
chondrial matrix marker, were determined in muscle homogenates
as described previously (Kirby et al, 2007).
Western blotting and Blue Native PAGE from patient tissues
Protein extraction from human skeletal muscle and fibroblast
samples for SDS–PAGE and subsequent Western blotting was
carried out as described previously (Thompson et al, 2016). Blue
Native PAGE was conducted on mitochondria isolated from skeletal
muscle and fibroblasts samples as described previously (Ola´hova´
et al, 2015) using antibodies against COXI (Abcam ab14705), SDHA
(Abcam ab14715), Porin/VDAC1 (Abcam ab14734), UQCRC2
(Abcam ab14745), NDUFB8 (Abcam ab110242), ATP5A (Abcam
ab14748), ATP5B (Abcam ab14730) and OXA1L (Proteintech 21055-
1-AP). All primary antibodies were used at a dilution of 1 in 1,000.
OXA1L siRNA depletion
siRNA SmartPool (Dharmacon, cat no M-012696-00) and individual
siRNA from the SmartPool (Dharmacon, cat no M-012696-03 and M-
012696-04) were used for transient depletion of OXA1L in U2OS cells.
Cells were incubated for 3 days with either siRNA targeting OXA1L or
with non-targeting siRNA, at the final concentration of 33 nM. The
siRNA was delivered using Lipofectamine RNAiMAX (Thermo Fisher
Scientific) diluted 1:1,000 in Opti-MEM I + GlutaMAX-I (Gibco), as
per manufacturer’s instructions. After 3 days, adherent cells were re-
transfected using the same conditions. At the end of the 6-day deple-
tion, cells were collected to performWestern blot analysis.
De novo mitochondrial protein synthesis
Mitochondrial protein synthesis in cultured cells was performed
essentially as described previously (Chomyn, 1996). Fibroblasts were
labelled for 1 h in methionine/cysteine-free DMEM (Sigma) with
200 lCi/ml of a [35S]-methionine/cysteine mixture (Perkin Elmer)
and 100 lg/ml emetine dihydrochloride (Sigma) followed by either 4
or 8 h chase in standard DMEM with additional 7.5 lg/ml cold
methionine. Aliquots (50 lg) of total cell protein were separated by
15% SDS–PAGE. Signals were detected using the Typhoon FLA9500
Phosphorimager and ImageQuant software (GE Healthcare).
Data availability
The dataset produced in this study is available in the following data-
base:
Clinical data: ClinVar accession numbers: SCV000803663 and
SCV000803664 (https://www.ncbi.nlm.nih.gov/clinvar/)
Expanded View for this article is available online.
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